RVSV Pseudotyped EBOV GP 

Order now: dominika@ksiazkiwnauce.pl

EBOV Soluble GP (sGP) ELISA kit

0100-001 IBT Bioservices 1ea 662.4 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA

Mouse anti-EBOV GP mAb (4F3)

0201-020 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Chimeric anti-EBOV GP mAb (c6D8)

0201-021 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Chimeric anti-EBOV GP mAb (h13F6)

0201-022 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Human anti-EBOV GP mAb (KZ52)

0260-001 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA

Rabbit anti-EBOV GP pAb Biotinylated

0301-015-bio IBT Bioservices 100ug 729.6 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV Soluble gp Protein [His]

VAng-Lsx0143-inquire Creative Biolabs inquire Ask for price
Description: EBOV sGP, recombinant protein from mammalian cells.

h HA-kRas G12V (GP)

LVP799-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: G12V mutant of kRas. Except the point mutation, the sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_004985. It also contains a GFP-Puromycin dual selection marker.

h VEGFA inducible lentiviral particles (GP)

LVP388-GP GenTarget 1 x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made inducible lentiviral particles for expressing human target: h VEGFA (alternative name: VPF; VEGF; MVCD1; MGC70609), with ORF sequence 100% matching to CDS region in NCBI ID: NM_001171626.1. Particles has GFP-Puromycin dual marker.

h CXCL12 inducible lentiviral particles (GP)

LVP698-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: CXCL12 (chemokine (C-X-C motif) ligand 12), [alternative names: IRH; PBSF; SCYB12; SDF1; TLSF; TPAR1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_199168.3. It also contains a GFP-Puromycin dual selection marker.

Chimeric anti-EBOV GP mAb (c13C6 FR1)

0201-023 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV Soluble GP (sGP) pAb

0365-001 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV gp Protein (aa 1-647)

VAng-Lsx0140-100g Creative Biolabs 100 µg 1210.8 EUR
Description: Ebola glycoprotein (aa 1-647), recombinant protein from 293 cell culture.

Recombinant EBOV gp Protein (Minus The Transmembrane Region) [His]

VAng-Lsx0141-inquire Creative Biolabs inquire Ask for price
Description: EBOV GPDTM, recombinant protein from Sf9 cells.

Recombinant EBOV gp Protein (Minus The Transmembrane Region) [HA]

VAng-Lsx0142-inquire Creative Biolabs inquire Ask for price
Description: EBOV GPDTM, recombinant protein from mammalian cells.

Recombinant EBOV GP-RBD Protein (aa 1-308) [Fc]

VAng-Wyb6914-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Recombinant EBOV GP-RBD Protein (aa 1-308) [Fc]

VAng-Wyb6914-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Recombinant EBOV GP-RBD Protein (aa 1-320) [Fc]

VAng-Wyb6917-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP-RBD Protein (aa 1-320) [Fc]

VAng-Wyb6917-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

NATtrol BC/GP Panel (10 X 0.75 mL)

NATBC/GP-NNS Zeptometrix 10 X 0.75 mL 751.39 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

Recombinant Reston EBOV gp Protein (Minus The Transmembrane Region) [His]

VAng-Lsx0145-inquire Creative Biolabs inquire Ask for price
Description: rREBOV GPDTM, recombinant protein from Sf9 cells.

Recombinant EBOV GP Protein (aa 1-501) [His] (HEK293 Cells)

VAng-Wyb6904-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-501) [His] (HEK293 Cells)

VAng-Wyb6904-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-637) [His] (HEK293 Cells)

VAng-Wyb6906-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-637) [His] (HEK293 Cells)

VAng-Wyb6906-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-650) [His] (HEK293 Cells)

VAng-Wyb6909-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-650) [His] (HEK293 Cells)

VAng-Wyb6909-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-501) [His] (Baculovirus-Insect Cells)

VAng-Wyb6903-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-501) [His] (Baculovirus-Insect Cells)

VAng-Wyb6903-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-637) [His] (Baculovirus-Insect Cells)

VAng-Wyb6905-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Sudan, strain Uganda-00) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-637) [His] (Baculovirus-Insect Cells)

VAng-Wyb6905-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Sudan, strain Uganda-00) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-650) [His] (Baculovirus-Insect Cells)

VAng-Wyb6908-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-650) [His] (Baculovirus-Insect Cells)

VAng-Wyb6908-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-650, 309-484 deleted) [His]

VAng-Wyb6910-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein (Virion spike glycoprotein), recombinant protein.

Recombinant EBOV GP Protein (aa 1-650, 309-484 deleted) [His]

VAng-Wyb6910-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein (Virion spike glycoprotein), recombinant protein.

Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA Kit, 48 tests, Quantitative

AE-320800-48 Alpha Diagnostics 1 kit 1074 EUR

Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA Kit, 96 tests, Quantitative

AE-320800-96 Alpha Diagnostics 1 kit 1804.8 EUR

Mouse Monoclonal Anti-Anti-Zaire Ebola virus glycoprotein (EBOV GP) IgG, purified

EVGP20-M Alpha Diagnostics 100 ul 578.4 EUR

Recombinant EBOV GP Protein (aa 1-650) [His] (subtype Zaire, strain Mayinga 1976)

VAng-Wyb6907-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Recombinant EBOV GP Protein (aa 1-650) [His] (subtype Zaire, strain Mayinga 1976)

VAng-Wyb6907-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Recombinant EBOV VP24

0501-030 IBT Bioservices 100ug 589.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

EBOV Delta Peptide

0509-001 IBT Bioservices 100ug 589.2 EUR
Description:
  • Related to: Staphylococcus
  • Applications: ELISA, WB

Recombinant EBOV VP40

0564-001 IBT Bioservices 100ug 589.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV Protein

VAng-Lsx0136-1mg Creative Biolabs 1 mg 1365.6 EUR
Description: EBOV, recombinant protein from E. coli.

Recombinant EBOV VLPs

VAng-Lsx0139-inquire Creative Biolabs inquire Ask for price
Description: EBOV Virus-Like Particles, recombinant protein from Sf9 cells.

GP-

EF017774 Lifescience Market 96 Tests 826.8 EUR

GP

EF013650 Lifescience Market 96 Tests 826.8 EUR

GP

EF006873 Lifescience Market 96 Tests 826.8 EUR

Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain Mayinga 1976)

VAng-Wyb6915-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain Mayinga 1976)

VAng-Wyb6915-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein.

Recombinant EBOV GPDTM (mammalian)

0501-001 IBT Bioservices 100ug 662.4 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV GPDTM (Sf9)

0501-015 IBT Bioservices 100ug 589.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV GPDTM (Sf9)

0501-016 IBT Bioservices 500ug 2179.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV GPDTM (S2)

0501-025 IBT Bioservices 100ug 662.4 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV GPDTM (S2)

0501-026 IBT Bioservices 500ug 2470.8 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Recombinant EBOV GPΔmuc (Sf9)

0511-015 IBT Bioservices 100ug 589.2 EUR
Description:
  • Related to: Staphylococcus
  • Applications: ELISA, WB

Recombinant EBOV Zaire NP

VAng-Lsx0137-inquire Creative Biolabs inquire Ask for price
Description: Recombinant Ebola Zaire Nucleoprotein (NP), contains the C-terminal portion of the Ebola Zaire nucleoprotein. Molecular weight is 15 kDa.

GP Antibody

1-CSB-PA350772LA01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA

GP Antibody

1-CSB-PA308957LA01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000

GP Antibody

1-CSB-PA310843LA01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA

GP Antibody

1-CSB-PA314099LA01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA

P-gp/ Rat P- gp ELISA Kit

ELA-E1690r Lifescience Market 96 Tests 1063.2 EUR

GP-IIbIIIa/ Rat GP- IIbIIIa ELISA Kit

ELA-E0614r Lifescience Market 96 Tests 1063.2 EUR

GP-IV/ Rat GP- IV ELISA Kit

ELA-E0674r Lifescience Market 96 Tests 1063.2 EUR

GP-BB/ Rat GP- BB ELISA Kit

ELA-E0845r Lifescience Market 96 Tests 1063.2 EUR

GP-MM/ Rat GP- MM ELISA Kit

ELA-E0848r Lifescience Market 96 Tests 1063.2 EUR

GP-II/ Rat GP- II ELISA Kit

ELA-E0849r Lifescience Market 96 Tests 1063.2 EUR

Rabbit anti-EBOV VLP antiserum

01-0004 IBT Bioservices 250uL 460.8 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV VP40 pAb

0301-010 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV NP pAb

0301-012 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV VP35 pAb

0301-040 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV VP24 pAb

0301-046 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV VP24 pAb

0301-047 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV VP30 pAb

0301-048 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV VLP pAb

0315-001 IBT Bioservices 500ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Rabbit anti-EBOV Delta Peptide

0366-001 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA

Recombinant EBOV Zaire NP [His]

VAng-Lsx0138-inquire Creative Biolabs inquire Ask for price
Description: Ebola Zaire nucleoprotein, recombinant protein from E. coli.

Recombinant EBOV VP40 Matrix Protein

VAng-Lsx0144-100g Creative Biolabs 100 µg 712.8 EUR
Description: EBOV VP40, recombinant protein from E. coli.

Recombinant HIV gp 120 and gp 41 Protein

VAng-0533Lsx-inquire Creative Biolabs inquire Ask for price
Description: HIV Chimeric Recombinant protein containing C-terminal of gp120 and most of gp41, expressed in E. coli. MW 27.3 kDa, 1.00 mg/mL.

Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15)

VAng-Wyb6916-100g Creative Biolabs 100 µg 2281.2 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15)

VAng-Wyb6916-20g Creative Biolabs 20 µg 940.8 EUR
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein.

proDynorphin (GP Reactive)

P10115 Neuromics 20 ug Blocking Peptide 175.2 EUR

GP(33-41)

HY-P0323 MedChemExpress 10mg 456 EUR

proDynorphin (GP Reactive)

GP10109 Neuromics 50 ul 321.6 EUR

GP Polyclonal Antibody

A64246-020 EpiGentek 20 ul 117.7 EUR

GP Polyclonal Antibody

A64246-050 EpiGentek 50 ul 302.5 EUR

GP Polyclonal Antibody

A64246-100 EpiGentek 100 ul 423.5 EUR

GP Polyclonal Antibody

A64254-020 EpiGentek 20 ul 117.7 EUR

GP Polyclonal Antibody

A64254-050 EpiGentek 50 ul 302.5 EUR

GP Polyclonal Antibody

A64254-100 EpiGentek 100 ul 423.5 EUR

GP Polyclonal Antibody

A64414-020 EpiGentek 20 ul 117.7 EUR

GP Polyclonal Antibody

A64414-050 EpiGentek 50 ul 302.5 EUR

GP Polyclonal Antibody

A64414-100 EpiGentek 100 ul 423.5 EUR

GP Polyclonal Antibody

A64246 EpiGentek
  • 684.66 EUR
  • 117.70 EUR
  • 302.50 EUR
  • 423.50 EUR
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

GP Polyclonal Antibody

A64254 EpiGentek
  • 684.66 EUR
  • 117.70 EUR
  • 302.50 EUR
  • 423.50 EUR
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

GP Polyclonal Antibody

A64414 EpiGentek
  • 684.66 EUR
  • 117.70 EUR
  • 302.50 EUR
  • 423.50 EUR
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

Mouse anti-EBOV VP40 mAb (3G5)

0201-016 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Mouse anti-EBOV VP40 mAb (5B12)

0201-017 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Mouse anti-EBOV VP40 mAb (AE11)

0201-018 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA

Rabbit anti-EBOV L-Polymerase pAb

0301-045 IBT Bioservices 100ug 577.2 EUR
Description:
  • Related to: Filoviruses
  • Applications: ELISA, WB

Ebola virus-like particles (EBOV VLP)

0550-001 IBT Bioservices 1mg 662.4 EUR
Description:
  • Related to: Filoviruses
  • Applications: WB

GP Antibody, HRP conjugated

1-CSB-PA350772LB01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

GP Antibody, FITC conjugated

1-CSB-PA350772LC01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

GP Antibody, Biotin conjugated

1-CSB-PA350772LD01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

GP Antibody, HRP conjugated

1-CSB-PA308957LB01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

GP Antibody, FITC conjugated

1-CSB-PA308957LC01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

GP Antibody, Biotin conjugated

1-CSB-PA308957LD01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

GP Antibody, HRP conjugated

1-CSB-PA310843LB01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

GP Antibody, FITC conjugated

1-CSB-PA310843LC01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

GP Antibody, Biotin conjugated

1-CSB-PA310843LD01ZAA Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

GP Antibody, HRP conjugated

1-CSB-PA314099LB01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA

GP Antibody, FITC conjugated

1-CSB-PA314099LC01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA

GP Antibody, Biotin conjugated

1-CSB-PA314099LD01ZAT Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA

Recombinant Ebola GP (Zaire)

DAGA-3111 Creative Diagnostics 100ug 1294.8 EUR

anti- GP repeat antibody

FNab03570 FN Test 100µg 702 EUR
Description: Antibody raised against GP repeat

Mouse GP ELISA Kit

EMG0349 Abclonal 96Tests 625.2 EUR

Human GP ELISA Kit

EHG0349 Abclonal 96Tests 625.2 EUR

Rat GP ELISA Kit

ERG0349 Abclonal 96Tests 625.2 EUR

Rabbit GP ELISA Kit

ERTG0349 Abclonal 96Tests 625.2 EUR

Porcine GP ELISA Kit

EPG0349 Abclonal 96Tests 625.2 EUR

Goat GP ELISA Kit

EGTG0349 Abclonal 96Tests 625.2 EUR

Bovine GP ELISA Kit

EBG0349 Abclonal 96Tests 625.2 EUR

Canine GP ELISA Kit

ECG0349 Abclonal 96Tests 625.2 EUR

Anserini GP ELISA Kit

EAG0349 Abclonal 96Tests 625.2 EUR

Anti-GP repeat antibody

PAab03570 Lifescience Market 100 ug 494.4 EUR

Recombinant MARV GP Protein

VAng-Wyb3477-50gEcoli Creative Biolabs 50 µg (E. coli) 3921.6 EUR
Description: Lake Victoria marburg virus (strain Angola/2005) envelope glycoprotein, recombinant protein.

Inactivated VZV gp Antigen

VAng-Lsx0551-inquire Creative Biolabs inquire Ask for price
Description: VZV Glycoprotein, natural protein.

Hanna GP Penetration Probe

THE0802 Scientific Laboratory Supplies EACH 68.4 EUR

Hanna GP Liquid Probe

THE4525 Scientific Laboratory Supplies EACH 87.78 EUR

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)

78172-1 BPS Bioscience 100 µl 835 EUR
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)

78172-2 BPS Bioscience 500 µl x 2 4195 EUR
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)

78204-1 BPS Bioscience 100 µl 835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. 

Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)

78204-2 BPS Bioscience 500 µl x 2 4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.

Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)

78205-1 BPS Bioscience 100 µl 835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)

78205-2 BPS Bioscience 500 µl x 2 4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)

78206-1 BPS Bioscience 100 µl 835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)

78206-2 BPS Bioscience 500 µl x 2 4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)

78215-1 BPS Bioscience 100 µl 900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)

78215-2 BPS Bioscience 500 µl x 2 4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)

78614-1 BPS Bioscience 100 µl 860 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)

78614-2 BPS Bioscience 500 µl x 2 4320 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

VSV-G Pseudotyped VSV Delta G (Luciferase Reporter)

78634-1 BPS Bioscience 100 µl 795 EUR
Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility.

VSV-G Pseudotyped VSV Delta G (Luciferase Reporter)

78634-2 BPS Bioscience 500 µl x 2 3995 EUR
Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

79942-1 BPS Bioscience 100 µl 875 EUR
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

79942-2 BPS Bioscience 500 µl x 2 4405 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

79981-1 BPS Bioscience 100 µl 875 EUR
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

79981-2 BPS Bioscience 500 µl x 2 5245 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Recombinant EBOV sGP Protein (aa 33-324)

VAng-0668Lsx-1mg Creative Biolabs 1 mg 7318.8 EUR
Description: Ebola virus BDBV (subtype Bundibugyo strain Uganda 2007) Small/secreted Glycoprotein (sGP), recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Recombinant EBOV sGP Protein (aa 33-324)

VAng-0668Lsx-50g Creative Biolabs 50 µg 1017.6 EUR
Description: Ebola virus BDBV (subtype Bundibugyo strain Uganda 2007) Small/secreted Glycoprotein (sGP), recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Recombinant EBOV Envelope Glycoprotein (aa 33-637)

VAng-0669Lsx-100g Creative Biolabs 100 µg 1017.6 EUR
Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Recombinant EBOV Envelope Glycoprotein (aa 33-637)

VAng-0669Lsx-1mg Creative Biolabs 1 mg 5998.8 EUR
Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus.

Human CellExp? Recombinant EBOV Envelope Glycoprotein 1

P1060-10 Biovision each 170.4 EUR

Human CellExp? Recombinant EBOV Envelope Glycoprotein 1

P1060-50 Biovision each 483.6 EUR

Recombinant HIV gp 120 and gp 41 (aa 485-631) Protein

VAng-0525Lsx-inquire Creative Biolabs inquire Ask for price
Description: HIV Chimeric Recombinant gp120 and gp41 (a.a. 485-631), recombinant protein from E. coli. MW 43 kDa, 2.70 mg/mL.

Western blot Kit for G. pig Primary Antibodies, Chemilum. Substrate

80206-Gp Alpha Diagnostics 1 kit 781.2 EUR

SV40 large T-antigen (GFP-Puro), CMV lentiviral particles

LVP016-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under suCMV promoter, containing GFP-puromycin fusion dual marker.

h PBK inducible lentiviral particles

LVP095-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made tet-inducible lentiviral particles expressing a human gene with a Blasticidin-RFP fusion marker (Dual selection). The expressed human gene, PBK, is fully sequence verified and matched to NCBI accession ID: NM_018492.2

h TERT inducible lentiviral particles

LVP105-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made tet-inducible lentiviral particles expressing a human gene with a GFP-Puromycin fusion marker (Dual selection). The expressed human gene, TERT, is fully sequence verified and matched to NCBI accession ID: NM_198253.2

m VSIR inducible lentiviral particles

LVP1070-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing mouse target: VSIR V-set immunoregulatory receptor), [alternative names: Dies1; PD-1H; VISTA]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_028732.4. It contains a GFP-Puromycin dual selection marker.

h CD274 (PDL1) (6His, GFP-Puro) inducible lentiviral particles

LVP1077-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a GFP-Puromycin dual selection marker.

h CD19 (GFP-Pueo) Lentivirus

LVP1084-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: CD19 (human CD19 molecule), [alternative names: B4; CVID3]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_001178098.1. It contains a GFP-Puromycin dual selection marker.

h SF3B1 (GFP-Puro)

LVP1111-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: SF3B1 (splicing factor 3b subunit 1), [alternative names: Hsh155; MDS; PRP10; PRPF10; SAP155; SF3b155]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_012433. It also contains a GFP-Puromycin dual selection marker.

h SRSF2 (GFP-Puro)

LVP1112-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: SRSF2 (serine and arginine rich splicing factor 2), [alternative names: PR264; SC-35; SC35; SFRS2; SFRS2A; SRp30b]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_003016. It also contains a GFP-Puromycin dual selection marker.

h U2AF1 (GFP-Puro)

LVP1113-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: U2AF1 (U2 small nuclear RNA auxiliary factor 1), [alternative names: FP793; RN; RNU2AF1; U2AF35; U2AFBP]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_001025203. It also contains a GFP-Puromycin dual selection marker.

h ZRSR2 (GFP-Puro)

LVP1118-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2), [alternative names: U2AF1-RS2; U2AF1L2; U2AF1RS2; URP; ZC3H22]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_005089. It also contains a GFP-Puromycin dual selection marker.

h RBM10 (GFP-Puro) Lentivirus

LVP1124-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: RBM10 (RNA binding motif protein 10), [alternative names: DXS8237E; GPATC9; GPATCH9; S1-1; TARPS; ZRANB5]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_005676.4 . It also contains a GFP-Puromycin dual selection marker.

h AKR1C3 (GFP-Puro) inducible lentiviral particles

LVP1129-GP GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Premade lentivirus natively over-express human AKR1C3 gene. It contains a GFP_Puromycin fusion dual marker.

hTERT (CMV, GFP-Puro) lentivirus

LVP1130-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing human TERT gene under suCMV promoter, containing GFP-Puromycin fusion dual marker.

hTERT (EF1a, GFP-Puro) lentivirus

LVP1131-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing human TERT gene under EF1a promoter, containing GFP-Puromycin fusion dual marker.

EBNA1 (GFP-Puro) Lentivirus

LVP1134-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing GFP-Puromycin dual marker.

EBNA2 (GFP-Puro) Lentivirus

LVP1135-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA2 gene under EF1a promoter, containing GFP-Puromycin dual marker.

HpV16-E6 (GFP-Puro) Lentivirus

LVP1136-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing HpV16 virus' E6 gene under EF1a promoter, containing GFP-Puromycin dual marker.

E1A (GFP-Puro) Lentivirus

LVP1137-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing Adenovirus type 5's E1A gene under EF1a promoter, containing GFP-Puromycin dual marker.

HOXA9 (GFP-Puro) Lentivirus

LVP1138-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing human HOXA9 gene under EF1a promoter, containing GFP-Puromycin dual marker.

KRas_G12V (GFP-Puro) Lentivirus

LVP1139-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing human Kras V12G mutant under EF1a promoter, containing GFP-Puromycin dual marker.

CDK4 (GFP-Puro) Lentivirus

LVP1140-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing human CDK4 gene under EF1a promoter, containing GFP-Puromycin dual marker.

cMyc (GFP-Puro) Lentivirus

LVP1141-GP GenTarget 1x107 IFU/ml x 200ul 418.8 EUR
Description: Premade lentivirus expressing human cMyc gene under EF1a promoter, containing GFP-Puromycin dual marker.

NATtrol Norovirus Group I (Recombinant) (Stool Matrix) (0.5 mL)

NATNOVI-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

NATtrol Norovirus Group II (Recombinant) (Stool Matrix) (0.5 mL)

NATNOVII-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

NATtrol Rotavirus (Stool Matrix) (0.5 mL)

NATROTA-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

NATtrol Shigella sonnei (Stool Matrix) (0.5 mL)

NATSSO-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

NATtrol Salmonella typhimurium (Stool Matrix) (0.5 mL)

NATSTY-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

NATtrol Adenovirus Type 40 (Stool Matrix) (0.5 mL)

NATADV40-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

NATtrol Adenovirus Type 41 (Stool Matrix) (0.5 mL)

NATADV41-GP Zeptometrix 0.5 mL 112.42 EUR
Description: Please contact Gentaur in order to receive the datasheet of the product.

RVSV Pseudotyped EBOV GP